apixaban
Eliquis (apixaban) is an oral factor Xa inhibitor from Bristol-Myers Squibb and Pfizer. By interrupting one key step of the clotting cascade it prevents harmful clots, and is used to reduce stroke risk in atrial fibrillation and to treat and prevent deep vein thrombosis and pulmonary embolism.
This page is based on FDA prescribing information and the EMA medicine record for apixaban, cross-checked with MedlinePlus; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
A blood clot forms like a chain of falling dominoes, with each clotting factor tipping over the next. Factor Xa is a domino near the end, right before the clot itself is built. Apixaban wedges that domino upright, so the cascade stops before the final piece ever falls.
In simple terms
When the body forms a clot, a series of proteins activate one another in a chain reaction. Apixaban directly blocks one of these proteins, factor Xa, which sits at a central point in the chain. With factor Xa inhibited, less thrombin is made and fewer clots form. This protects against clots that can cause stroke in atrial fibrillation or travel from the legs to the lungs.
In depth
Apixaban is a selective inhibitor of FXa. It does not require antithrombin III for antithrombotic activity. The absolute bioavailability of apixaban is approximately 50% for doses up to 10 mg of ELIQUIS. It inhibits both free and clot-bound factor Xa and prothrombinase activity, reducing thrombin generation without directly inhibiting thrombin itself. By preserving some thrombin generation for haemostasis while curbing pathological amplification, it lowers the risk of venous and arterial thrombosis; it requires no routine coagulation monitoring.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How apixaban selectively inhibits factor Xa
- When the body forms a clot, a series of proteins activate one another in a chain reaction.
- Apixaban is a selective inhibitor of FXa. It does not require antithrombin III for antithrombotic activity.
- It inhibits both free and clot-bound factor Xa and prothrombinase activity, reducing thrombin generation without directly inhibiting thrombin itself.
- By preserving some thrombin generation for haemostasis while curbing pathological amplification, it lowers the risk of venous and arterial thrombosis; it requires no routine coagulation monitoring.
Target: Coagulation factor Xa
The enzyme at the convergence point of the clotting cascade that converts prothrombin into thrombin; throttling it reduces thrombin generation and new fibrin clot formation.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- To reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation
- Prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in adults who have undergone hip or knee replacement surgery
- Treatment of deep vein thrombosis and pulmonary embolism
- To reduce the risk of recurrent deep vein thrombosis and pulmonary embolism following initial therapy
Approved uses in European Union
EMA- Prevention of venous thromboembolic events in adults who have undergone elective hip or knee replacement surgery
- Prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation and one or more risk factors, such as prior stroke or transient ischaemic attack, age 75 years or older, hypertension, diabetes mellitus or symptomatic heart failure
- Treatment of deep vein thrombosis and pulmonary embolism, and prevention of recurrent deep vein thrombosis and pulmonary embolism, in adults
- Treatment of venous thromboembolism and prevention of recurrent venous thromboembolism in paediatric patients from 28 days to less than 18 years of age
Official sources
The statements on this page trace back to these records.
- Eliquis (apixaban) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- U.S. Food and Drug Administration: apixaban prescribing information
U.S. Food and Drug Administration
- MedlinePlus: apixaban
MedlinePlus, U.S. National Library of Medicine
- National Cancer Institute: apixaban
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.